Quick Answer
Fulcrum Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $197.53 million for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +239.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $7.98 million | Q3 2018: $82.76 million | Q1 2019: $62.45 million | Q2 2019: $49.63 million | Q3 2019: $101.60 million | Q1 2020: $25.38 million | Q2 2020: $75.72 million | Q3 2020: $85.22 million | Q1 2021: $100.75 million | Q2 2021: $56.78 million | Q3 2021: $65.47 million | Q1 2022: $33.31 million | Q2 2022: $40.15 million | Q3 2022: $90.94 million | Q1 2023: $34.73 million | Q2 2023: $33.97 million | Q3 2023: $30.08 million | Q1 2024: $39.95 million | Q2 2024: $86.70 million | Q3 2024: $72.63 million | Q1 2025: $42.18 million | Q2 2025: $42.59 million | Q3 2025: $47.08 million.
- Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 171.3%.
- Historical annual values: Fiscal year 2025: $197.53 million | Fiscal year 2024: $58.21 million | Fiscal year 2023: $25.56 million | Fiscal year 2022: $35.10 million | Fiscal year 2021: $35.41 million | Fiscal year 2020: $57.05 million | Fiscal year 2019: $96.71 million | Fiscal year 2018: $72.80 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: